These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18608912)

  • 101. Cryptococcus neoformans- and Cryptococcus gattii-specific IgG, IgA and IgM differ among children and adults with and without cryptococcosis from Colombia.
    Becerra-Álvarez P; Escandón P; Lizarazo J; Quirós-Gómez Ó; Firacative C
    Med Mycol; 2022 Sep; 60(9):. PubMed ID: 36066645
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection.
    Lortholary O; Improvisi L; Rayhane N; Gray F; Fitting C; Cavaillon JM; Dromer F
    Infect Immun; 1999 Dec; 67(12):6314-20. PubMed ID: 10569743
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Antibody binding to Cryptococcus neoformans impairs budding by altering capsular mechanical properties.
    Cordero RJ; Pontes B; Frases S; Nakouzi AS; Nimrichter L; Rodrigues ML; Viana NB; Casadevall A
    J Immunol; 2013 Jan; 190(1):317-23. PubMed ID: 23233725
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Induction of protective immunity against cryptococcosis.
    Wozniak KL; Hardison S; Olszewski M; Wormley FL
    Mycopathologia; 2012 Jun; 173(5-6):387-94. PubMed ID: 22143898
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Detection of antibody against fungal glucosylceramide in immunocompromised patients: a potential new diagnostic approach for cryptococcosis.
    Qureshi A; Wray D; Rhome R; Barry W; Del Poeta M
    Mycopathologia; 2012 Jun; 173(5-6):419-25. PubMed ID: 21971701
    [TBL] [Abstract][Full Text] [Related]  

  • 106. [Serological tests for diagnosing fungal infections].
    Lass-Flörl C
    Wien Med Wochenschr; 2007; 157(19-20):526-9. PubMed ID: 18030559
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Glucuronoxylomannan intranasal challenge prior to Cryptococcus neoformans pulmonary infection enhances cerebral cryptococcosis in rodents.
    Lee HH; Carmichael DJ; Ríbeiro V; Parisi DN; Munzen ME; Charles-Niño CL; Hamed MF; Kaur E; Mishra A; Patel J; Rooklin RB; Sher A; Carrillo-Sepulveda MA; Eugenin EA; Dores MR; Martinez LR
    PLoS Pathog; 2023 Apr; 19(4):e1010941. PubMed ID: 37115795
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Antibody-mediated immobilization of Cryptococcus neoformans promotes biofilm formation.
    Robertson EJ; Casadevall A
    Appl Environ Microbiol; 2009 Apr; 75(8):2528-33. PubMed ID: 19251903
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Cryptococcal interactions with the host immune system.
    Voelz K; May RC
    Eukaryot Cell; 2010 Jun; 9(6):835-46. PubMed ID: 20382758
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T-cell proliferation.
    Vecchiarelli A; Retini C; Monari C; Casadevall A
    Infect Immun; 1998 Mar; 66(3):1244-7. PubMed ID: 9488420
    [TBL] [Abstract][Full Text] [Related]  

  • 111.
    Yoon H; Nakouzi A; Pappas PG; Hemmige VS; Pirofski LA
    Open Forum Infect Dis; 2022 Jul; 9(7):ofac211. PubMed ID: 35794949
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Microbial polysaccharide: new insights for treating autoimmune diseases.
    Vecchiarelli A; Monari C
    Front Biosci (Schol Ed); 2010 Jan; 2(1):256-67. PubMed ID: 20036945
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Toward identification of the genetic risk profile for cryptococcal disease in HIV-infected patients.
    Netea MG
    mBio; 2013 Oct; 4(5):e00798-13. PubMed ID: 24129259
    [TBL] [Abstract][Full Text] [Related]  

  • 114. [Not Available].
    Mitaka H; Perlman DC
    CMAJ; 2022 Nov; 194(46):E1591-E1592. PubMed ID: 36442876
    [No Abstract]   [Full Text] [Related]  

  • 115. Treatment recommendations for non-HIV associated cryptococcal meningoencephalitis including management of post-infectious inflammatory response syndrome.
    Ssebambulidde K; Anjum SH; Hargarten JC; Chittiboina P; Shoham S; Seyedmousavi S; Marr KA; Hammoud DA; Billioux BJ; Williamson PR
    Front Neurol; 2022; 13():994396. PubMed ID: 36530631
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Identification of Disease-Associated Cryptococcal Proteins Reactive With Serum IgG From Cryptococcal Meningitis Patients.
    Gressler AE; Volke D; Firacative C; Schnabel CL; Müller U; Krizsan A; Schulze-Richter B; Brock M; Brombacher F; Escandón P; Hoffmann R; Alber G
    Front Immunol; 2021; 12():709695. PubMed ID: 34367172
    [No Abstract]   [Full Text] [Related]  

  • 117. Antibody responses to Cryptococcus neoformans in Indian patients with cryptococcosis.
    Saha DC; Xess I; Zeng WY; Goldman DL
    Med Mycol; 2008 Aug; 46(5):457-63. PubMed ID: 18608912
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection.
    Abadi J; Pirofski La
    J Infect Dis; 1999 Sep; 180(3):915-9. PubMed ID: 10438394
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Analysis of antibody response to Cryptococcus neoformans in five patients with AIDS and cryptococcosis by immunoblotting.
    Lamura L; Matthews RC; Barchiesi F; Donahoe M; Burnie JP; Scalise G
    J Infect; 2000 Jan; 40(1):64-8. PubMed ID: 10762114
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.
    Zhang H; Zhong Z; Pirofski LA
    Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.